18F-FDG PET/MRI与MRI在原发性宫颈癌治疗前肿瘤分期中的比较
该前瞻性研究纳入53例经组织病理学证实的原发性宫颈癌患者,比较全身18F-FDG PET/MRI与单独MRI在局部肿瘤评估和全身分期中的诊断效能及对治疗决策的影响。PET/MRI正确判定T分期45/53例(85%),MRI为46/53例(87%);PET/MRI在淋巴结转移和远处转移检测中灵敏度、特异度及准确率均高于MRI。在分期结果不一致的患者中,PET/MRI使更多患者(9例)获得正确治疗推荐,而MRI为3例。
要点
- PET/MRI正确判定T分期45/53例(85%),MRI为46/53例(87%)。
- PET/MRI检测淋巴结阳性患者灵敏度83%、特异度90%、准确率87%,MRI分别为71%、83%、77%。
- PET/MRI检测远处转移灵敏度87% vs MRI 67%,特异度92% vs 90%,准确率91% vs 83%。
核心结论
- 研究结果表明,整合PET/MRI成功应用于宫颈癌患者的全身肿瘤分期,与单独MRI相比可改善治疗计划。
研究设计与样本
- 前瞻性纳入53例经组织病理学证实的原发性宫颈癌患者,行全身18F-FDG PET/MRI检查。
- 两名有经验的医师按第7版AJCC分期手册分别判读MRI和PET/MRI数据并进行TNM分期。
- 随后在模拟多学科肿瘤委员会中讨论两种影像结果并记录治疗决策;以组织病理学和横断面影像随访为参考标准。
主要发现
- PET/MRI正确判定T分期45/53例(85%),MRI正确判定46/53例(87%)。
- 53例中24例存在淋巴结转移;PET/MRI检测淋巴结阳性患者的灵敏度83%、特异度90%、准确率87%,MRI分别为71%、83%、77%。
- PET/MRI检测远处转移的灵敏度87% vs MRI 67%,特异度92% vs 90%,诊断准确率91% vs 83%。
- 在两种影像分期结果不一致的患者中,PET/MRI使更多患者(n=9)获得正确治疗推荐,MRI为n=3。
关键数值与推荐
- T分期正确判定:PET/MRI 45/53例(85%),MRI 46/53例(87%)。
- 淋巴结阳性患者检测:PET/MRI灵敏度83%、特异度90%、准确率87%;MRI灵敏度71%、特异度83%、准确率77%。
- 远处转移检测:PET/MRI灵敏度87%、特异度92%、诊断准确率91%;MRI灵敏度67%、特异度90%、诊断准确率83%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of the present study was to assess and compare the diagnostic performance of integrated PET/MRI and MRI alone for local tumor evaluation and whole-body tumor staging of primary cervical cancers. In addition, the corresponding impact on further patient management of the two imaging modalities was assessed. METHODS: A total of 53 consecutive patients with histopathological verification of a primary cervical cancer were prospectively enrolled for a whole-body 18F-FDG PET/MRI examination. Two experienced physicians analyzed the MRI data, in consensus, followed by a second reading session of the PET/MRI datasets. The readers were asked to perform a dedicated TNM staging in accordance with the 7th edition of the AJCC staging manual. Subsequently, the results of MRI and PET/MRI were discussed in a simulated interdisciplinary tumor board and therapeutic decisions based on both imaging modalities were recorded. Results from histopathology and cross-sectional imaging follow-up served as the reference standard. RESULTS: PET/MRI allowed for a correct determination of the T stage in 45/53 (85%) cases, while MRI alone enabled a correct identification of the tumor stage in 46/53 (87%) cases. In 24 of the 53 patients, lymph node metastases were present. For the detection of nodal-positive patients, sensitivity, specificity and accuracy of PET/MRI were 83%, 90% and 87%, respectively. The respective values for MRI alone were 71%, 83% and 77%. In addition, PET/MRI showed higher values for the detection of distant metastases than MRI alone (sensitivity: 87% vs. 67%, specificity: 92% vs. 90%, diagnostic accuracy: 91% vs. 83%). Among the patients with discrepant staging results in the two imaging modalities, PET/MRI enabled correct treatment recommendations for a higher number (n = 9) of patients than MRI alone (n = 3). CONCLUSION: The present results demonstrate the successful application of integrated PET/MRI imaging for whole-body tumor staging of cervical cancer patients, enabling improved treatment planning when compared to MRI alone.
引用
- Sarabhai T, Schaarschmidt BM, Wetter A, et al. Comparison of 18F-FDG PET/MRI and MRI for pre-therapeutic tumor staging of patients with primary cancer of the uterine cervix. Eur J Nucl Med Mol Imaging. 2017. PMID: 28840302. doi:10.1007/s00259-017-3809-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。